Cardiff Oncology, Inc. (CRDF)

Market Cap	217.87M
Revenue (ttm)	683,000
Net Income (ttm)	-45.46M
Shares Out	66.52M
EPS (ttm)	-0.95
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	521,186
Open	3.470
Previous Close	3.440
Day's Range	3.260 - 3.465
52-Week Range	2.010 - 6.380
Beta	1.73
Analysts	Strong Buy
Price Target	12.00 (+266.41%)
Earnings Date	May 1, 2025

About CRDF

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. The company’s lead drug candidate is Onvansertib, an oral, small molecule drug candidate that is highly specific for PLK1 inhibition. It also focuses clinical program in indications, such as RAS-mutated metastatic colorectal cancer, as well as investigator-initiated ongoing or planned trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer; CRDF-004, a Phase 2 o...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 33
• Stock Exchange: NASDAQ
• Ticker Symbol: CRDF
• Website: https://www.cardiffoncology.com

Financial Performance

In 2024, Cardiff Oncology's revenue was $683,000, an increase of 39.96% compared to the previous year's $488,000. Losses were -$45.46 million, 9.62% more than in 2023.

Analyst Forecast

According to 4 analysts, the average rating for CRDF stock is "Strong Buy." The 12-month stock price forecast is $12.0, which is an increase of 266.41% from the latest price.

Price Target

$12.0

(266.41% upside)

Analyst Consensus: Strong Buy